Agilent Technologies, Inc.

New York Stock Exchange
Back to all articles
Somewhat Bullish +50

Agilent Names New Chief Legal Officer Amid Leadership Transition

🗂️ Agilent Technologies Inc. has appointed Michael Buckner as its new Chief Legal Officer, effective May 4, 2026.

👋 Bret DiMarco is stepping down from his roles as senior vice president, chief legal officer, and secretary on the same date.

🤝 DiMarco will transition into a special advisor role until December 1, 2026, to assist with the handover of responsibilities.

💼 Buckner brings nearly 30 years of experience from Danaher Corp., where he served as vice president and deputy general counsel.

⚖️ His background includes leading global legal teams for complex transactions, governance, and regulatory matters at major firms like General Electric.

📈 TipRanks analysts rate Agilent (A) stock as a Buy with a $140.00 price target.

🧠 Spark's AI Analyst gives Agilent a Neutral rating based on solid fundamentals but notes a weak technical setup.

💰 Positive factors include maintained growth guidance, raised EPS, and margin-expansion plans offset by a high P/E ratio.

🔬 Agilent reported fiscal 2025 revenue of $6.95 billion across analytical and clinical laboratory technologies.

👥 The company employs approximately 18,000 people worldwide focusing on instruments, software, and services for scientific research.

Bullish Signals
  • Agilent appointed Michael Buckner as its new Chief Legal Officer on May 4, 2026, bringing nearly 30 years of experience in complex transactions and governance.
  • Buckner joins from Danaher Corp., where he drove major deals including high-profile acquisitions and spin-offs, expected to strengthen Agilent's legal strategy as it advances its growth plans.
  • Analysts maintain a Buy rating on Agilent with a $140.00 price target.
  • The company reported fiscal 2025 revenue of $6.95 billion and employs about 18,000 people worldwide.
  • Agilent has maintained its growth guidance and raised EPS for the upcoming period.
  • Management outlined plans for margin expansion and tariff mitigation to support future profitability.
Risk Factors
  • Bret DiMarco resigned from his roles as senior vice president, chief legal officer, and secretary on May 4, 2026, indicating a significant leadership transition amidst ongoing operations.
  • The stock exhibits a weak technical setup characterized by trading below key moving averages with negative momentum, signaling potential downside pressure.
  • Despite maintaining growth guidance, the valuation presents risks due to a relatively high P/E ratio coupled with a low dividend yield.
  • Recent analyst consensus includes conflicting signals between a 'Buy' rating and a 'Neutral' AI score, creating uncertainty in investment sentiment.
Full Analysis
Agilent Technologies Inc. has appointed Michael Buckner as its new Chief Legal Officer, effective May 4, 2026. He succeeds Bret DiMarco, who resigned from his roles as senior vice president, chief legal officer, and secretary on the same date pursuant to a previously disclosed transition agreement. DiMarco will continue with the company as a special advisor until December 1, 2026, to facilitate a smooth handover of responsibilities. Buckner joins Agilent from Danaher Corp., where he served as vice president, deputy general counsel, and chief M&A counsel, bringing nearly three decades of experience in complex transactions, governance, and regulatory matters. His background includes leading global legal teams and driving major deals such as high-profile acquisitions and spin-offs at Danaher, with earlier roles at General Electric. This appointment is expected to strengthen Agilent's legal strategy as it advances its growth plans and manages regulatory and transactional risk across its global operations. Agilent Technologies Inc., a global leader in analytical and clinical laboratory technologies, reported fiscal 2025 revenue of $6.95 billion and employs approximately 18,000 people worldwide. The company provides instruments, software, services, and scientific expertise to customers engaged in complex research and diagnostic settings. Its market presence spans analytical labs and clinical environments, where its platforms enable testing, measurement, and analysis across pharmaceuticals, life sciences, diagnostics, and related industries. Analysts note solid underlying fundamentals and a constructive earnings-call outlook, including maintained growth guidance, raised EPS estimates, and plans for margin expansion and tariff mitigation, though concerns remain regarding a weak technical setup and relatively high P/E ratio.